Companies /Healthcare

Halozyme Therapeutics Inc

NASDAQ: HALO Biotechnology
$93.04
▼ $2.76 (−2.88%) today
Markets closed · 4:23am ET

24/7 Wall St. View

HALO at a Glance

Valuation
Market cap
$10.9B
P/E ratio
24.0
Profitability
Revenue (TTM)
$1.8B
Profit margin
26.9%
EPS (TTM)
$4.00
Price
52-week range
$61 – $134
24/7 target
$102.02
Street target
$119.89
Earnings
Next report
Jan 26, 2027

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: HALO halozyme.com

About Halozyme Therapeutics

Halozyme Therapeutics is a biopharmaceutical company that earns most of its revenue by licensing drug delivery technologies to pharmaceutical partners.

Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to enable subcutaneous delivery of injected drugs and fluids that would otherwise be given intravenously. ENHANZE is used in ten commercialized products across more than 100 markets. It is licensed to partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai, Acumen, Merus, GSK and Incyte. Key royalty contributors are argenx's VYVGART Hytrulo, Janssen's DARZALEX SC and Roche's Phesgo.

Halozyme generates revenue in three ways:
- Royalties on partner product sales.
- Product sales, including bulk rHuPH20 API, its proprietary products Hylenex and XYOSTED, and auto-injector drug-device combination products partnered with Teva and Viatris affiliate McDermott Laboratories.
- Collaborative agreement revenue from upfront payments, target nominations and milestones.

Through its acquisitions of Elektrofi and Surf Bio in late 2025, the company added two hyperconcentration technologies that reduce injection volume for the same dose. Hypercon is a microparticle technology licensed to Janssen, Eli Lilly, argenx, Vertex and Oruka. Aerocon is a polymer-based technology. Both are intended to complement ENHANZE.

Halozyme actively enforces its MDASE patent portfolio. This includes litigation against Merck over subcutaneous Keytruda (Keytruda Qlex). Updated

Latest Activity

HALOHalozyme Therapeutics
Q3 2026
EPS
$2.39
est $2.35+1.7%
Revenue
$493M
est $491M+0.4%

ENHANZE royalties jumped 44% to a record $341 million, and management raised full-year non-GAAP EPS guidance to $8.75-$9.05. The royalty engine is now carrying the story, even as shares slipped in the minutes after the release.

Quarterly EPS — reported vs estimate

HALO Coverage

8:04am ET
Investing

Analysts Just Upgraded these Five Stocks

Live Updates No updates were posted during this live coverage. Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR | PLTR Price…

Ian Cooper
9:22am ET
Investing

Add These 5 Hot Biotech Stocks In July

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re investing…

Joshua Rodriguez
8:45am ET
Health and Healthcare

Halozyme Therapeutics Wins Big on Roche License Agreement

Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed therapeutic…

Chris Lange
1:15pm ET
Health and Healthcare

Halozyme Therapeutics Sinks on Business Update

Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.

Chris Lange

Frequently Asked Questions

What does Halozyme Therapeutics do?

Halozyme Therapeutics is a biopharmaceutical company that earns most of its revenue by licensing drug delivery technologies to pharmaceutical partners.

What is the HALO stock price target?

24/7 Wall St.'s 12-month price target for HALO is $102.02, rated Buy. The Wall Street consensus target is $119.89. HALO price prediction →